US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Medicus Pharma Ltd.

0.1614

-0.0090-5.28%

Post-market: 0.1595-0.0019-1.18%19:59 EDT

Volume:18.16M

Turnover:3.14M

Market Cap:10.20M

PE:-0.10

High:0.1724

Open:0.1718

Low:0.1570

Close:0.1704

52wk High:3.05

52wk Low:0.1512

Shares:63.18M

Float Shares:56.90M

Volume Ratio:0.64

T/O Rate:31.92%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.6597

EPS(LYR):-2.7356

ROE:-7446.11%

ROA:-110.67%

PB:-5.78

PE(LYR):-0.06

Loading ...

Overview Company News Filings

Medicus Pharma submits IND to Abu Dhabi health regulator for Teverelix endometriosis trial

Medicus Pharma Initiates Groundbreaking Precision-E2 Phase 2a Study of Teverelix® in Endometriosis Utilizing the Emirati Genome Program

THOMSON REUTERS

Medicus Pharma Submits European Application for Prostate Cancer Drug Study

MT Newswires Live

Medicus Pharma submits substantial modification application through EU CTIS

Medicus Pharma submits EU CTIS application to amend Teverelix Phase 2b trial plan

Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients With Key European Submission

THOMSON REUTERS

Medicus Pharma Shareholders Approve Auditor, Board and Consolidation

Medicus Pharma shareholders approve board authority for up to 1-for-50 share consolidation

Analysts Are Bullish on Top Healthcare Stocks: Health Catalyst (HCAT), Medicus Pharma Ltd (MDCX)

Medicus Pharma submits Protocol SKNJCT-005 to the FDA

Medicus Pharma submits FDA protocol for SkinJect registrational Gorlin syndrome study

Medicus Pharma Advances Skinject® Into Registrational Development for Gorlin Syndrome

THOMSON REUTERS

Medicus Pharma secures up to $22 million structured financing facility with institutional investor

Medicus Pharma Announces $22 Million Non-Dilutive Financing

THOMSON REUTERS

Medicus Pharma Secures Financing Amid Nasdaq Compliance Pressure

Medicus Pharma enters USD 22.86 million secured note deal with Streeterville Capital

Medicus Pharma reports Q1 EPS (31c), consensus (22c)

Medicus Pharma Ltd reports results for the quarter ended December 31 - Earnings Summary

Medicus Pharma Q1 EPS $(0.31) Misses $(0.19) Estimate

Benzinga Earnings

Medicus Pharma Ltd - Q1 2026 Net Loss per Share $0.31

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/stock/MDCX/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"MDCX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCX\",,,,,undefined,":{"symbol":"MDCX","market":"US","secType":"STK","nameCN":"Medicus Pharma Ltd.","latestPrice":0.1614,"timestamp":1789070400000,"preClose":0.1704,"halted":0,"volume":18164197,"hourTrading":{"tag":"盘后","latestPrice":0.159501,"preClose":0.1614,"latestTime":"19:59 EDT","volume":887286,"amount":142298.89452,"timestamp":1789084777801,"change":-0.001899,"changeRate":-0.011766,"amplitude":0.043371},"delay":0,"changeRate":-0.05281690140845075,"floatShares":56901000,"shares":63180610,"eps":-1.659689,"marketStatus":"Closed","change":-0.009,"latestTime":"09-10 16:00:00 EDT","open":0.1718,"high":0.1724,"low":0.157,"amount":3142930.2997254203,"amplitude":0.090376,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.659689,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789113600000},"marketStatusCode":5,"adr":0,"listingDate":1731560400000,"exchange":"NASDAQ","adjPreClose":0.1704,"preHourTrading":{"tag":"盘前","latestPrice":0.17,"preClose":0.1704,"latestTime":"09:29 EDT","volume":6612869,"amount":1170465.11629152,"timestamp":1789046999371,"change":-0.0004,"changeRate":-0.002347,"amplitude":0.158451},"postHourTrading":{"tag":"盘后","latestPrice":0.159501,"preClose":0.1614,"latestTime":"19:59 EDT","volume":887286,"amount":142298.89452,"timestamp":1789084777801,"change":-0.001899,"changeRate":-0.011766,"amplitude":0.043371},"volumeRatio":0.643152},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCX\",,,,,undefined,":{"symbol":"MDCX","floatShares":56901000,"roa":"-110.67%","roe":"-7446.11%","lyrEps":-2.735593,"volumeRatio":0.643152,"shares":63180610,"dividePrice":0,"high":0.1724,"amplitude":0.090376,"preClose":0.1704,"low":0.157,"week52Low":0.1512,"pbRate":"-5.78","week52High":3.05,"institutionHeld":0,"latestPrice":0.1614,"eps":-1.659689,"divideRate":0,"volume":18164197,"delay":0,"ttmEps":-1.659689,"open":0.1718,"prevYearClose":1.53,"prevWeekClose":0.172,"prevMonthClose":0.2618,"prevQuarterClose":0.4463,"fiveDayClose":0.2599,"twentyDayClose":0.3311,"sixtyDayClose":0.32},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MDCX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"MDCX","fiscalQuarterEnding":"2026/06","expectedEps":-0.14,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"post","actualEps":-0.21},{"market":"US","date":"2026-05-14","symbol":"MDCX","fiscalQuarterEnding":"2026/03","expectedEps":-0.18,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"post","actualEps":-0.31},{"market":"US","date":"2026-03-25","symbol":"MDCX","fiscalQuarterEnding":"2025/12","expectedEps":-0.32,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774411200000,"reportTimeType":"post","actualEps":-0.82},{"date":"2025-11-14","symbol":"MDCX","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1763154000000,"name":null,"time":"Post-Mkt","dateTimestamp":1763096400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MDCX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MDCX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1785297600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MDCX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MDCX","date":"2026-09-09","current":-0.097247,"percent":1,"low":-3.23298,"twenty":-2.167912,"median":-0.736109,"eighty":-0.336268,"high":-0.189555,"avg":-1.083424,"sd":0.948792,"marketCap":10740703},"quantilePoints":[{"date":"2025-08-29","current":-2.084531,"twenty":-2.272139,"median":-2.126221,"eighty":-2.109545,"marketCap":35632532},{"date":"2025-09-05","current":-1.907346,"twenty":-2.205434,"median":-2.115799,"eighty":-2.053263,"marketCap":32603766},{"date":"2025-09-12","current":-2.345097,"twenty":-2.211687,"median":-2.12101,"eighty":-2.053263,"marketCap":40086598},{"date":"2025-09-19","current":-2.532705,"twenty":-2.511859,"median":-2.178335,"eighty":-2.080362,"marketCap":43293526},{"date":"2025-09-26","current":-2.817408,"twenty":-2.759151,"median":-2.287772,"eighty":-2.103292,"marketCap":48160186},{"date":"2025-10-03","current":-3.005474,"twenty":-2.869667,"median":-2.511859,"eighty":-2.115799,"marketCap":51374941},{"date":"2025-10-10","current":-3.005474,"twenty":-2.994879,"median":-2.558762,"eighty":-2.122052,"marketCap":51374941},{"date":"2025-10-17","current":-2.885734,"twenty":-2.976858,"median":-2.720313,"eighty":-2.151236,"marketCap":49328130},{"date":"2025-10-24","current":-2.909682,"twenty":-2.974342,"median":-2.774974,"eighty":-2.174166,"marketCap":49737492},{"date":"2025-10-31","current":-2.957578,"twenty":-2.974342,"median":-2.817408,"eighty":-2.178335,"marketCap":50556216},{"date":"2025-11-07","current":-2.897708,"twenty":-2.962368,"median":-2.809662,"eighty":-2.228364,"marketCap":49532811},{"date":"2025-11-14","current":-2.706124,"twenty":-2.950394,"median":-2.817408,"eighty":-2.292984,"marketCap":46257915},{"date":"2025-11-21","current":-1.28141,"twenty":-2.950394,"median":-2.789942,"eighty":-2.178335,"marketCap":44939453},{"date":"2025-11-28","current":-1.355609,"twenty":-2.936025,"median":-2.763,"eighty":-2.119968,"marketCap":48464116},{"date":"2025-12-05","current":-1.183077,"twenty":-2.916866,"median":-2.742046,"eighty":-2.04284,"marketCap":42295956},{"date":"2025-12-12","current":-1.201563,"twenty":-2.904892,"median":-2.700137,"eighty":-1.376181,"marketCap":42956830},{"date":"2025-12-19","current":-1.022869,"twenty":-2.897708,"median":-2.63428,"eighty":-1.31987,"marketCap":36568379},{"date":"2025-12-26","current":-0.955088,"twenty":-2.897553,"median":-2.584818,"eighty":-1.266827,"marketCap":34145173},{"date":"2026-01-02","current":-1.074791,"twenty":-2.896932,"median":-2.511859,"eighty":-1.220048,"marketCap":38424640},{"date":"2026-01-09","current":-1.095865,"twenty":-2.885734,"median":-2.329463,"eighty":-1.179996,"marketCap":39178064},{"date":"2026-01-16","current":-0.976444,"twenty":-2.885734,"median":-2.178335,"eighty":-1.123965,"marketCap":34908660},{"date":"2026-01-23","current":-0.94132,"twenty":-2.866576,"median":-2.167912,"eighty":-1.101485,"marketCap":33652952},{"date":"2026-01-30","current":-0.878097,"twenty":-2.861786,"median":-2.115799,"eighty":-1.061072,"marketCap":31392680},{"date":"2026-02-06","current":-0.765701,"twenty":-2.861786,"median":-2.074108,"eighty":-1.022014,"marketCap":27374416},{"date":"2026-02-13","current":-0.709738,"twenty":-2.853549,"median":-1.933403,"eighty":-0.974021,"marketCap":25373688},{"date":"2026-02-20","current":-0.786136,"twenty":-2.850483,"median":-1.381324,"eighty":-0.961937,"marketCap":28104981},{"date":"2026-02-27","current":-0.97195,"twenty":-2.849812,"median":-1.344224,"eighty":-0.949581,"marketCap":34747976},{"date":"2026-03-06","current":-0.484474,"twenty":-2.849812,"median":-1.300152,"eighty":-0.949581,"marketCap":17320333},{"date":"2026-03-13","current":-0.412761,"twenty":-2.835443,"median":-1.263181,"eighty":-0.891018,"marketCap":14756541},{"date":"2026-03-20","current":-0.412761,"twenty":-2.825864,"median":-1.220048,"eighty":-0.847322,"marketCap":14756541},{"date":"2026-03-27","current":-0.387698,"twenty":-2.82079,"median":-1.201563,"eighty":-0.836077,"marketCap":18330934},{"date":"2026-04-02","current":-0.349652,"twenty":-2.811211,"median":-1.179996,"eighty":-0.820403,"marketCap":16532085},{"date":"2026-04-10","current":-0.367967,"twenty":-2.792337,"median":-1.125793,"eighty":-0.786136,"marketCap":17398052},{"date":"2026-04-17","current":-0.250001,"twenty":-2.775573,"median":-1.109135,"eighty":-0.744685,"marketCap":11820441},{"date":"2026-04-24","current":-0.276475,"twenty":-2.764797,"median":-1.099378,"eighty":-0.508201,"marketCap":13072156},{"date":"2026-05-01","current":-0.235266,"twenty":-2.75402,"median":-1.088841,"eighty":-0.417566,"marketCap":11123732},{"date":"2026-05-08","current":-0.277717,"twenty":-2.74923,"median":-1.069002,"eighty":-0.412761,"marketCap":13130880},{"date":"2026-05-15","current":-0.393186,"twenty":-2.733353,"median":-1.041354,"eighty":-0.401798,"marketCap":18590424},{"date":"2026-05-22","current":-0.308017,"twenty":-2.714637,"median":-1.024243,"eighty":-0.38811,"marketCap":15777036},{"date":"2026-05-29","current":-0.354651,"twenty":-2.703729,"median":-1.018593,"eighty":-0.376126,"marketCap":18165658},{"date":"2026-06-05","current":-0.402361,"twenty":-2.691755,"median":-0.976444,"eighty":-0.374724,"marketCap":20609444},{"date":"2026-06-12","current":-0.35842,"twenty":-2.672597,"median":-0.968141,"eighty":-0.372398,"marketCap":18358733},{"date":"2026-06-18","current":-0.378775,"twenty":-2.63428,"median":-0.962395,"eighty":-0.367967,"marketCap":19401342},{"date":"2026-06-26","current":-0.492235,"twenty":-2.63428,"median":-0.955088,"eighty":-0.371628,"marketCap":25212882},{"date":"2026-07-02","current":-0.442458,"twenty":-2.59471,"median":-0.94132,"eighty":-0.37203,"marketCap":22663265},{"date":"2026-07-10","current":-0.467347,"twenty":-2.543128,"median":-0.915037,"eighty":-0.3732,"marketCap":23938074},{"date":"2026-07-17","current":-0.449095,"twenty":-2.516028,"median":-0.871896,"eighty":-0.374395,"marketCap":23003214},{"date":"2026-07-24","current":-0.424981,"twenty":-2.511859,"median":-0.846653,"eighty":-0.374627,"marketCap":21768066},{"date":"2026-07-31","current":-0.290474,"twenty":-2.411802,"median":-0.843141,"eighty":-0.371929,"marketCap":14878433},{"date":"2026-08-07","current":-0.34025,"twenty":-2.326336,"median":-0.835949,"eighty":-0.363051,"marketCap":17428051},{"date":"2026-08-14","current":-0.353971,"twenty":-2.282561,"median":-0.821824,"eighty":-0.360424,"marketCap":20056990},{"date":"2026-08-21","current":-0.30351,"twenty":-2.211687,"median":-0.793282,"eighty":-0.354379,"marketCap":17197762},{"date":"2026-08-28","current":-0.298604,"twenty":-2.178335,"median":-0.778989,"eighty":-0.346389,"marketCap":16919767},{"date":"2026-09-04","current":-0.190112,"twenty":-2.172081,"median":-0.757549,"eighty":-0.339549,"marketCap":10772294},{"date":"2026-09-09","current":-0.189555,"twenty":-2.167912,"median":-0.736109,"eighty":-0.336268,"marketCap":10740703}],"updateTime":1789096295338},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MDCX\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2642454289","title":"Medicus Pharma submits IND to Abu Dhabi health regulator for Teverelix endometriosis trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2642454289","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642454289?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:30","pubTimestamp":1781177458,"startTime":"0","endTime":"0","summary":"Medicus Pharma submitted an IND application to Abu Dhabi’s Department of Health for its PRECISION-E2 Phase 2a Teverelix study in endometriosis.The genomics-enabled trial plans to enroll about 84 women in the UAE, leveraging participants in the Emirati Genome Program.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDL5rSc3Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2210149790.SGD","NDAQ","IE00BGHQF748.EUR","LU2210150020.SGD","BK4112","MDCX","IE00BN0W2T93.GBP","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014039.USD","BK4585","IE00B64PRP62.GBP","IE00BN0W2W23.USD","LU0314104364.USD","BK4588","SG9999014013.SGD","IE00BN0W2V16.EUR","LU2095319765.USD","SG9999014005.SGD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642289118","title":"Medicus Pharma Initiates Groundbreaking Precision-E2 Phase 2a Study of Teverelix® in Endometriosis Utilizing the Emirati Genome Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2642289118","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642289118?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:30","pubTimestamp":1781177400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nTUA8BXT9F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641048470","title":"Medicus Pharma Submits European Application for Prostate Cancer Drug Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2641048470","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641048470?lang=en_us&edition=fundamental","pubTime":"2026-06-08 20:55","pubTimestamp":1780923301,"startTime":"0","endTime":"0","summary":"Medicus Pharma  submitted a clinical modification application with the European Union to support an upcoming phase 2b trial of its advanced prostate cancer treatment Teverelix, the drugmaker said Monday.The phase 2b study aims to refine dosage options and analyze the safety, efficacy, and biological behavior of the therapy before starting registrational development, the company said.The drug candidate targets prostate cancer patients who have an elevated risk for cardiovascular issues and require androgen deprivation therapy, Medicus Pharma said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDCX","BK4139","EPV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641489731","title":"Medicus Pharma submits substantial modification application through EU CTIS","url":"https://stock-news.laohu8.com/highlight/detail?id=2641489731","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641489731?lang=en_us&edition=fundamental","pubTime":"2026-06-08 19:37","pubTimestamp":1780918661,"startTime":"0","endTime":"0","summary":"Medicus Pharma (MDCX) announced the submission of a substantial modification application through the European Union Clinical Trials Information Sys...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/medicus-pharma-submits-substantial-modification-application-through-eu-ctis-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/medicus-pharma-submits-substantial-modification-application-through-eu-ctis-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPV","BK4156","MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641489134","title":"Medicus Pharma submits EU CTIS application to amend Teverelix Phase 2b trial plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2641489134","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641489134?lang=en_us&edition=fundamental","pubTime":"2026-06-08 19:30","pubTimestamp":1780918240,"startTime":"0","endTime":"0","summary":"Medicus Pharma filed a substantial modification via the EU CTIS to support a planned Phase 2b Teverelix study in advanced prostate cancer.The application is under regulatory review; enrollment is targeted for later this year, subject to authorization.The trial is intended to support registrational planning focused on prostate cancer patients with elevated cardiovascular risk on androgen deprivation therapy.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDL5fsmPG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","BK4588","SG9999014039.USD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4139","LU2210149790.SGD","BK4585","IE00BN0W2T93.GBP","LU2095319765.USD","IE00BN0W2W23.USD","LU0314104364.USD","BK4112","IE00B64PRP62.GBP","NDAQ","IE00BN0W2V16.EUR","LU2210150020.SGD","SG9999014013.SGD","SG9999014021.USD","IE00BKPKM429.USD","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641941489","title":"Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients With Key European Submission","url":"https://stock-news.laohu8.com/highlight/detail?id=2641941489","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641941489?lang=en_us&edition=fundamental","pubTime":"2026-06-08 19:30","pubTimestamp":1780918201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nTUAB0STJL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641826198","title":"Medicus Pharma Shareholders Approve Auditor, Board and Consolidation","url":"https://stock-news.laohu8.com/highlight/detail?id=2641826198","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641826198?lang=en_us&edition=fundamental","pubTime":"2026-06-05 06:34","pubTimestamp":1780612461,"startTime":"0","endTime":"0","summary":"An update from Medicus Pharma Ltd ( ($MDCX) ) is now available. On June 3, 2026, Medicus Pharma Ltd. held its 2026 Annual General and Special Meeti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-shareholders-approve-auditor-board-and-consolidation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-shareholders-approve-auditor-board-and-consolidation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641016783","title":"Medicus Pharma shareholders approve board authority for up to 1-for-50 share consolidation","url":"https://stock-news.laohu8.com/highlight/detail?id=2641016783","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641016783?lang=en_us&edition=fundamental","pubTime":"2026-06-05 04:32","pubTimestamp":1780605129,"startTime":"0","endTime":"0","summary":"Medicus Pharma held its annual general and special meeting on June 3, 2026.Shareholders ratified KPMG LLP as independent registered public accounting firm for fiscal 2026; the board was authorized to set fees and terms.Shareholders approved a special resolution authorizing the board to consolidate common shares, at its discretion, up to a 50-for-1 ratio.The share consolidation was authorized but not executed; any consolidation remains subject to a separate board determination on timing and ratio.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL2Srn84:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640165061","title":"Analysts Are Bullish on Top Healthcare Stocks: Health Catalyst (HCAT), Medicus Pharma Ltd (MDCX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640165061","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640165061?lang=en_us&edition=fundamental","pubTime":"2026-06-04 23:20","pubTimestamp":1780586409,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Health Catalyst (HCAT) and Medicus Pharma Ltd (MDCX)...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-health-catalyst-hcat-medicus-pharma-ltd-mdcx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-health-catalyst-hcat-medicus-pharma-ltd-mdcx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MDCX","BK4167","HCAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640079989","title":"Medicus Pharma submits Protocol SKNJCT-005 to the FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2640079989","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640079989?lang=en_us&edition=fundamental","pubTime":"2026-06-03 21:37","pubTimestamp":1780493843,"startTime":"0","endTime":"0","summary":"Medicus Pharma (MDCX) announced the submission of Protocol SKNJCT-005 to the FDA under the company’s existing investigational new drug, or IND, app...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/medicus-pharma-submits-protocol-sknjct-005-to-the-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/medicus-pharma-submits-protocol-sknjct-005-to-the-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","MDCX","IND","BK4585","LABU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640901615","title":"Medicus Pharma submits FDA protocol for SkinJect registrational Gorlin syndrome study","url":"https://stock-news.laohu8.com/highlight/detail?id=2640901615","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640901615?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:01","pubTimestamp":1780488108,"startTime":"0","endTime":"0","summary":"Medicus submitted a Phase 2b registrational protocol for SkinJect in Gorlin syndrome under its existing FDA IND.Trial targets up to 50 patients; primary endpoint is complete visual clearance in at least 50% of selected lesions at Week 10.FDA orphan drug designation application filed in April; incentives could include waiver of NDA fees above USD 5 million, seven years of exclusivity.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief on June 03, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL713kk1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640901569","title":"Medicus Pharma Advances Skinject® Into Registrational Development for Gorlin Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2640901569","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640901569?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:00","pubTimestamp":1780488001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nTUABNVXFF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638981146","title":"Medicus Pharma secures up to $22 million structured financing facility with institutional investor","url":"https://stock-news.laohu8.com/highlight/detail?id=2638981146","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638981146?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:03","pubTimestamp":1779969816,"startTime":"0","endTime":"0","summary":"Medicus Pharma entered a definitive structured financing facility of up to USD 22 million with an institutional investor.USD 12 million will be funded immediately; USD 10 million will be held in a collateralized deposit account for milestone-based releases.Facility includes a USD 12.86 million secured promissory note at 8.75% interest with a 6.5% original issue discount.Second tranche is a USD 10 million secured promissory note at 5% interest with no original issue discount.Pro forma cash is expected to rise to about USD 30 million; projected operating runway exceeds 24 months; notes mature in 18 months.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL39VCP7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2095319765.USD","SG9999014005.SGD","LU0314104364.USD","BK4139","BK4112","IE00BN0W2W23.USD","NDAQ","SG9999014039.USD","SG9999014013.SGD","MDCX","IE00BN0W2T93.GBP","BK4588","IE00BGHQF748.EUR","LU2210150020.SGD","SG9999014021.USD","BK4585","IE00BKPKM429.USD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638698623","title":"Medicus Pharma Announces $22 Million Non-Dilutive Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2638698623","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638698623?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:00","pubTimestamp":1779969607,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nTUAC3YKWN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638634807","title":"Medicus Pharma Secures Financing Amid Nasdaq Compliance Pressure","url":"https://stock-news.laohu8.com/highlight/detail?id=2638634807","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638634807?lang=en_us&edition=fundamental","pubTime":"2026-05-28 06:19","pubTimestamp":1779920379,"startTime":"0","endTime":"0","summary":"An announcement from Medicus Pharma Ltd ( ($MDCX) ) is now available. On May 27, 2026, Medicus Pharma Ltd. closed a $22.86 million secured financin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-secures-financing-amid-nasdaq-compliance-pressure?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-secures-financing-amid-nasdaq-compliance-pressure?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MDCX","NQmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638856639","title":"Medicus Pharma enters USD 22.86 million secured note deal with Streeterville Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2638856639","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638856639?lang=en_us&edition=fundamental","pubTime":"2026-05-28 04:45","pubTimestamp":1779914735,"startTime":"0","endTime":"0","summary":"Medicus Pharma closed a note purchase agreement with Streeterville Capital for two secured promissory notes totaling USD 22.86 million.Streeterville funded USD 12 million at closing; another USD 10 million was placed in a controlled deposit account at Lakeside Bank.Secured Promissory Note A-1 carries 8.75% interest, an USD 834,225 original issue discount; matures 18 months from issuance.Secured Promissory Note B carries 5% interest; no original issue discount; matures 18 months from issuance.About USD 2.5 million repaid and extinguished a YA II PN debenture; proceeds earmarked for clinical development, business development, general corporate uses.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL1shSs3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635643724","title":"Medicus Pharma reports Q1 EPS (31c), consensus (22c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635643724","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635643724?lang=en_us&edition=fundamental","pubTime":"2026-05-15 06:18","pubTimestamp":1778797121,"startTime":"0","endTime":"0","summary":"“During the first quarter of 2026, Medicus continued to execute on its transformation into a diversified clinical-stage biotechnology company, high...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/medicus-pharma-reports-q1-eps-31c-consensus-22c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/medicus-pharma-reports-q1-eps-31c-consensus-22c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635729315","title":"Medicus Pharma Ltd reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635729315","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635729315?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:00","pubTimestamp":1778792454,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd reports results for the quarter ended December 31 - Earnings SummaryMedicus Pharma Ltd MDCX.OQ reported a quarterly adjusted loss of 31 cents per share for the quarter ended Decembe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL8N41R2JD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635726585","title":"Medicus Pharma Q1 EPS $(0.31) Misses $(0.19) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635726585","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635726585?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:34","pubTimestamp":1778790882,"startTime":"0","endTime":"0","summary":"Medicus Pharma (NASDAQ:MDCX) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.19) by 63.16 percent. This is a 26.19 percent increase over losses of $(0.42) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52582192/medicus-pharma-q1-eps-0-31-misses-0-19-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Medicus Pharma Q1 EPS $(0.31) Misses $(0.19) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635726743","title":"Medicus Pharma Ltd - Q1 2026 Net Loss per Share $0.31","url":"https://stock-news.laohu8.com/highlight/detail?id=2635726743","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635726743?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:30","pubTimestamp":1778790601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUA8M1DKT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":3,"totalSize":105,"code":"91000000","status":"200"}]}}